[u'-----BEGIN PRIVACY-ENHANCED MESSAGE-----\nProc-Type: 2001,MIC-CLEAR\nOriginator-Name: webmaster@www.sec.gov\nOriginator-Key-Asymmetric:\n MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen\n TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB\nMIC-Info: RSA-MD5,RSA,\n NGwiljVhMQYSRDuSo2/DROjp4f62jKmSkxShLaHY7v2yJLYMsU4zedrtOxPOO/+L\n v0dgEcwEnNrIl9g9+piGkg==\n\n', u'0000950134-04-014240.txt : 20040928\n', u'0000950134-04-014240.hdr.sgml : 20040928\n', u'20040928161631\nACCESSION NUMBER:\t\t0000950134-04-014240\nCONFORMED SUBMISSION TYPE:\t8-K/A\nPUBLIC DOCUMENT COUNT:\t\t8\nCONFORMED PERIOD OF REPORT:\t20040715\nITEM INFORMATION:\t\tCompletion of Acquisition or Disposition of Assets\nITEM INFORMATION:\t\tResults of Operations and Financial Condition\nITEM INFORMATION:\t\tFinancial Statements and Exhibits\nFILED AS OF DATE:\t\t20040928\nDATE AS OF CHANGE:\t\t20040928\n\nFILER:\n\n\tCOMPANY DATA:\t\n\t\tCOMPANY CONFORMED NAME:\t\t\tAMERICAN MEDICAL SYSTEMS HOLDINGS INC\n\t\tCENTRAL INDEX KEY:\t\t\t0001114200\n\t\tSTANDARD INDUSTRIAL CLASSIFICATION:\tORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]\n\t\tIRS NUMBER:\t\t\t\t134018241\n\t\tSTATE OF INCORPORATION:\t\t\tDE\n\t\tFISCAL YEAR END:\t\t\t1229\n\n\tFILING VALUES:\n\t\tFORM TYPE:\t\t8-K/A\n\t\tSEC ACT:\t\t1934 Act\n\t\tSEC FILE NUMBER:\t000-30733\n\t\tFILM NUMBER:\t\t041050116\n\n\tBUSINESS ADDRESS:\t\n\t\tSTREET 1:\t\t10700 BREN ROAD WEST\n\t\tCITY:\t\t\tMINNETONKA\n\t\tSTATE:\t\t\tMN\n\t\tZIP:\t\t\t55343\n\t\tBUSINESS PHONE:\t\t9529334666\n\n\tMAIL ADDRESS:\t\n\t\tSTREET 1:\t\t10700 BREN ROAD WEST\n\t\tCITY:\t\t\tMINNETONKA\n\t\tSTATE:\t\t\tMN\n\t\tZIP:\t\t\t55343\n', u'\n', u'\n', u'8-K/A\n', u'1\n', u'c88445e8vkza.htm\n', u'AMENDMENT TO FORM 8-K\n', u'\n', u'e8vkza', u'\n', u' PAGEBREAK ', u'\n', u'Table of Contents', u'\n', u'\n', u'\n', u'\n', u'UNITED STATES', u'\nSECURITIES AND EXCHANGE COMMISSION\n\n', u'Washington, D.C. 20549\n', u'\n', u'FORM 8-K/A\n\n\n', u'CURRENT REPORT', u'\n', u'Pursuant to Section\xa013 or 15(d) of the', u'\nSecurities Exchange Act of 1934', u'\n', u'\n', u'\n', u'\n', u'Date of Report (Date of earliest event reported): ', u'July\xa015, 2004', u'\n', u'AMERICAN MEDICAL SYSTEMS HOLDINGS, INC.', u'\n', u'(Exact name of registrant as specified in its charter)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Delaware', u'\n', u'\n', u'\xa0', u'\n', u'000-30733', u'\n', u'\n', u'\xa0', u'\n', u'41-1978822', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u'\xa0', u'\n', u'\xa0\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(State or other jurisdiction', u'\nof incorporation)\n', u'\n', u'\xa0', u'\n', u'(Commission', u'\nFile Number)\n', u'\n', u'\xa0', u'\n', u'(I.R.S. Employer', u'\nIdentification No.)', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'10700 Bren Road West', u'\nMinnetonka, MN 55343', u'\n(Address of principal executive offices)\n\n\n\n', u'(952)\xa0930-6000', u'\n(Registrant\x92s telephone number, including area code)\n\n\n\n', u'\n', u'\n', u'\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\n', u' TOC ', u'\n', u'TABLE OF CONTENTS', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'Item\xa02.01. Completion of Acquisition or Disposition of Assets', u'\n', u'Item\xa02.02. Results of Operations and Financial Condition', u'\n', u'Item\xa09.01. Financial Statements and Exhibits', u'\n', u'SIGNATURES', u'\n', u'INDEX TO EXHIBITS', u'\n', u'Consent of Benham, Ichen & Knox, LLP, Independent Auditors', u'\n', u'Audited Balance Sheet', u'\n', u'Unaudited Balance Sheets', u'\n', u'Unaudited Pro Forma Financial Information', u'\n', u'Press Release', u'\n', u'\n', u'\n', u' /TOC ', u'\n', u'\n', u'Table of Contents', u'\n', u' link1 "Item&nbsp;2.01. Completion of Acquisition or Disposition of Assets" ', u'\n', u'\n', u'Item\xa02.01. Completion of Acquisition or Disposition of Assets.', u'\n', u'\xa0\xa0\xa0\xa0\xa0This Form 8-K/A is being filed to amend the Form 8-K filed on July\xa029,\n2004 by American Medical Systems Holdings, Inc. (the \x93Company\x94) to include the\nfinancial statements and financial information referred to in Item\xa09.01 below\nwhich relate to the acquisition of TherMatrx, Inc., a Delaware corporation\n(\x93TherMatrx\x94) by American Medical Systems, Inc. (\x93AMS\x94), a wholly owned\nsubsidiary of the Company.\n\n\n', u'\xa0\xa0\xa0\xa0\xa0On July\xa015, 2004, AMS completed the previously announced acquisition of\nTherMatrx. Pursuant to the Agreement and Plan of Merger, dated as of June\xa015,\n2004, among AMS; Leio Acquisition Corp., a Delaware corporation and wholly\nowned subsidiary of AMS (\x93Merger Subsidiary\x94); TherMatrx; TherMatrx Investment\nHoldings LLC and BSD Medical Corporation, principal stockholders; and TherMatrx\nInvestment Holdings LLC, as stockholders\x92 representative, Merger Subsidiary\nmerged with and into TherMatrx, with TherMatrx surviving and continuing as a\nwholly-owned subsidiary of AMS.\n\n', u' link1 "Item&nbsp;2.02. Results of Operations and Financial Condition" ', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0', u'Item\xa02.02. Results of Operations and Financial Condition.', u'\n', u'On July\xa029, 2004, the Company issued a press release announcing results for its\nsecond quarter of fiscal year 2004. Attached hereto as Exhibit\xa099.4 is a copy\nof the Company\x92s press release dated July\xa029, 2004 announcing the Company\x92s\nresults of operations.\n\n\n', u'The information contained under this Item\xa02.02 and Exhibit\xa099.4 hereto shall\nnot be deemed \x93filed\x94 for purposes of Section\xa018 of the Securities Exchange Act\nof 1934, as amended (the \x93Exchange Act\x94), or incorporated by reference in any\nfiling under the Securities Act of 1933, as amended, or the Exchange Act,\nexcept as shall be expressly set forth by specific reference in such a filing.\n\n\n', u' link1 "Item&nbsp;9.01. Financial Statements and Exhibits" ', u'\n', u'\n', u'\xa0\xa0\xa0\xa0\xa0', u'Item\xa09.01. Financial Statements and Exhibits.', u'\n', u'\xa0\xa0\xa0\xa0\xa0(a)\xa0', u'Financial statements of businesses acquired. ', u'The financial statements\nof TherMatrx are attached hereto as Exhibits 99.1 and 99.2 and are incorporated\nherein by reference.\n\n\n', u'\xa0\xa0\xa0\xa0\xa0(b)\xa0', u'Pro forma financial information. ', u'The pro forma financial information\nis attached hereto as Exhibit\xa099.3 and is incorporated herein by reference.\n\n\n', u'\xa0\xa0\xa0\xa0\xa0(c)\xa0', u'Exhibits', u'. The following materials are filed as exhibits to this\ncurrent report on Form 8-K/A.\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Exhibit No.', u'\n', u'\xa0', u'\n', u'Description', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2.1\n', u'\n', u'\xa0', u'\n', u'Agreement and Plan of Merger, dated as of June\xa015, 2004, among\nAmerican Medical Systems, Inc.; Leio Acquisition Corp.;\nTherMatrx, Inc.; TherMatrx Investments Holdings LLC and BSD\nMedical Corporation, as Principal Stockholders, and TherMatrx\nInvestments Holdings LLC, as Stockholders\x92 Representative\n(previously filed with the Securities and Exchange Commission\nas an exhibit to AMS Holding\x92s Report on Form\xa08-K filed on\nJune\xa016, 2004 and incorporated herein by reference).', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'23.1\n', u'\n', u'\xa0', u'\n', u'Consent of Benham, Ichen & Knox, LLP, Independent Auditors.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'99.1\n', u'\n', u'\xa0', u'\n', u'Audited balance sheet of TherMatrx as of September\xa030, 2003,\nand 2002 and the statements of income and retained earnings,\nand cash flows for the years then ended.', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'2\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'Table of Contents', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Exhibit No.', u'\n', u'\xa0', u'\n', u'Description', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'99.2\n', u'\n', u'\xa0', u'\n', u'Unaudited balance sheets of TherMatrx as of June\xa030, 2004 and\nSeptember\xa030, 2003 and the statements of income and retained\nearnings and cash flows for the three and nine month periods\nended June\xa030, 2004 and 2003, including notes to the financial\nstatements.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'99.3\n', u'\n', u'\xa0', u'\n', u'Unaudited pro forma financial information.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'99.4\n', u'\n', u'\xa0', u'\n', u'Press Release dated July\xa029, 2004.', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'3\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'Table of Contents', u'\n', u'\n', u' link1 "SIGNATURES" ', u'\n', u'\n', u'SIGNATURES', u'\n', u'\xa0\xa0\xa0\xa0\xa0Pursuant to the requirements of the Securities Exchange Act of 1934, the\nregistrant has duly caused this report to be signed on its behalf by the\nundersigned hereunto duly authorized.\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'AMERICAN MEDICAL SYSTEMS\nHOLDINGS, INC.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'By:\n', u'\n', u'\xa0', u'\n', u'/s/ Carmen L. Diersen', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Carmen L. Diersen', u'\nExecutive Vice President and ', u'\nChief Financial Officer', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'Dated: September\xa028, 2004\n\n\n', u'4\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'Table of Contents', u'\n', u'\n', u' link1 "INDEX TO EXHIBITS" ', u'\n', u'\n', u'INDEX TO EXHIBITS\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Exhibit No.', u'\n', u'\xa0', u'\n', u'Description', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2.1\n', u'\n', u'\xa0', u'\n', u'Agreement and Plan of Merger, dated as of June\xa015, 2004, among\nAmerican Medical Systems, Inc.; Leio Acquisition Corp.;\nTherMatrx, Inc.; TherMatrx Investments Holdings LLC and BSD\nMedical Corporation, as Principal Stockholders, and TherMatrx\nInvestments Holdings LLC, as Stockholders\x92 Representative\n(previously filed with the Securities and Exchange Commission\nas an exhibit to AMS Holding\x92s Report on Form\xa08-K filed on\nJune\xa016, 2004 and incorporated herein by reference).', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'23.1\n', u'\n', u'\xa0', u'\n', u'Consent of Benham, Ichen & Knox, LLP, Independent Auditors.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'99.1\n', u'\n', u'\xa0', u'\n', u'Audited balance sheet of TherMatrx as of September\xa030, 2003,\nand 2002 and the statements of income and retained earnings,\nand cash flows for the years then ended.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'99.2\n', u'\n', u'\xa0', u'\n', u'Unaudited balance sheets of TherMatrx as of June\xa030, 2004 and\nSeptember\xa030, 2003 and the statements of income and retained\nearnings and cash flows for the three and nine month periods\nended June\xa030, 2004 and 2003, including notes to the financial\nstatements.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'99.3\n', u'\n', u'\xa0', u'\n', u'Unaudited pro forma financial information.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'99.4\n', u'\n', u'\xa0', u'\n', u'Press Release dated July\xa029, 2004.', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'5\n', u'\n', u'\n', u'\n', u'\n', u'EX-23.1\n', u'2\n', u'c88445exv23w1.htm\n', u'CONSENT OF BENHAM, ICHEN & KNOX, LLP, INDEPENDENT AUDITORS\n', u'\n', u'exv23w1', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'EXHIBIT 23.1\n\n\n', u'\n', u'\xa0\n\n\n', u'September\xa020, 2004\n\n\n\n', u'Kathie Lenzen', u'\nAmerican Medical Systems', u'\n10700 Bren Road West', u'\nMinnetonka, MN 55343 USA\n\n\n', u'\nWe have audited the financial statements of Thermatrx, Inc. as of September\xa030, 2003 and 2002\nand for the periods then ended for the purpose of expressing an\nopinion as to whether the\nfinancial statements present fairly, in all material respects, the financial position, results of\noperations, and cash flows of Thermatrx, Inc. in conformity with generally accepted\naccounting principles.\n\n\n', u'We give permission for the\nuse of our audit reported dated November\xa010, 2003, except for Note\n12 as to which the date is July\xa028, 2004, to be used in the filing of Form\xa08K.\n\n\n', u'\n', u'\n', u'Benham, Ichen & Knox, LLP\n\n', u'\xa0\n\n\n\n', u'1117 S. MILWAUKEE AVENUE,\nFORUM SQUARE BLDG. C, SUITE 11 \x95 LIBERTYVILLE, ILLINOIS 60048-3763', u'\nVOICE: (847)\xa0362-4310 \x95 FACSIMILE: (847)\xa0362-5016 \x95 E-MAIL: info@bikcpa.com', u'\nWEBSITE: www.bikcpa.com\n\n\n\n', u'6\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.1\n', u'3\n', u'c88445exv99w1.htm\n', u'AUDITED BALANCE SHEET\n', u'\n', u'exv99w1', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'EXHIBIT 99.1\n\n\n', u'\n', u'INDEPENDENT AUDITORS\x92 REPORT', u'\n', u'To the Board of Directors', u'\nTherMatrx, Inc.', u'\nNorthbrook, IL 60062\n\n', u'We have audited the accompanying balance sheets of TherMatrx, Inc. as of\nSeptember\xa030, 2003 and 2002, and the related statements of income and retained\nearnings and cash flows for the years then ended. These financial statements\nare the responsibility of the Company\x92s management. Our responsibility is to\nexpress an opinion on these financial statements based on our audits.\n\n\n', u'We conducted our audits in accordance with auditing standards generally\naccepted in the United States of America. Those standards require that we plan\nand perform the audits to obtain reasonable assurance about whether the\nfinancial statements are free of material misstatement. An audit includes\nexamining, on a test basis, evidence supporting the amounts and disclosures in\nthe financial statements. An audit also includes assessing the accounting\nprinciples used and significant estimates made by management, as well as\nevaluating the overall financial statement presentation. We believe that our\naudits provide a reasonable basis for our opinion.\n\n\n', u'In our opinion, the financial statements referred to above present fairly, in\nall material respects, the financial position of TherMatrx, Inc. as of\nSeptember\xa030, 2003 and 2002, and the results of its operations and its cash\nflows for the years then ended in conformity with accounting principles\ngenerally accepted in the United States of America.\n\n\n', u'\xa0', u'\nSincerely,\n\n\n', u'Benham, Ichen & Knox LLP\n\n\n\n', u'November\xa010, 2003, except for Note 12', u'\nas to which the date is July\xa028, 2004\n\n\n', u'7\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nBalance Sheets', u'\n(In thousands, except share and per share data)\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'September 30, 2003', u'\n', u'\xa0', u'\n', u'September 30, 2002', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash and cash equivalents', u'\n', u'\xa0', u'\n', u'$', u'\n', u'660', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'694', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Short term investments', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts receivable, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,238', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,816', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Inventories, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,486', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,780', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'154', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'268', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,548', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,568', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Property, plant and equipment, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'319', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'311', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Intangibles, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,017', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,238', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Investment in technology and other assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'44', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'36', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total assets', u'\n', u'\xa0', u'\n', u'$', u'\n', u'8,928', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'7,153', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Liabilities and Stockholders\x92 Equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts payable', u'\n', u'\xa0', u'\n', u'$', u'\n', u'325', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'258', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other accrued expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'912', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'654', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Deferred revenue and customer deposits', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'964', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,053', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,201', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,965', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Long-term liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'550', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'537', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Common stock, par value $.001 per share; authorized\n14,000,000 shares; issued and outstanding:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,225,321 shares', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,101', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,101', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Preferred stock, par value $.001 per share; authorized\n6,000,000 shares; issued and outstanding:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'5,175,000 shares', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,500', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,500', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Retained earnings', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(6,424', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(7,950', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,177', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,651', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total liabilities and stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'$', u'\n', u'8,928', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'7,153', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'The accompanying notes are an integral part of the financial statements.', u'\n', u'8\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nStatements of Income and Retained Earnings', u'\n(In thousands)\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Year Ended', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'September 30, 2003', u'\n', u'\xa0', u'\n', u'September 30, 2002', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Net sales', u'\n', u'\xa0', u'\n', u'$', u'\n', u'13,290', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'7,360', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cost of sales', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,693', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,986', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Gross profit', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,597', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,374', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Marketing and selling', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,543', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,662', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Research and development', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'996', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'849', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'General and administrative', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,400', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,846', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'8,939', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,357', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'658', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,983', u'\n', u')', u'\n', u'\n', u'\n', u'Other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Licensing revenue, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'873', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Interest income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'19', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Interest expense', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(8', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'868', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'19', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Income before income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,526', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,964', u'\n', u')', u'\n', u'\n', u'\n', u'Provision for income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income', u'\n', u'\xa0', u'\n', u'$', u'\n', u'1,526', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($1,964', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Retained earnings, beginning of year', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($7,950', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($5,986', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Retained earnings, end of year', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(6,424', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(7,950', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'The accompanying notes are an intergral part of the financal statements.', u'\n', u'9\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nStatements of Cash Flow', u'\n(In thousands)\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Year Ended', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'September 30, 2003', u'\n', u'\xa0', u'\n', u'September 30, 2002', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Cash flows from operating activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income', u'\n', u'\xa0', u'\n', u'$', u'\n', u'1,526', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($1,964', u'\n', u')', u'\n', u'\n', u'\n', u'Adjustments to reconcile net income to\nnet cash provided by operating activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Depreciation', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'351', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'295', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Changes in operating assets and liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts receivable', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(422', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,714', u'\n', u')', u'\n', u'\n', u'\n', u'Inventories', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,714', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(968', u'\n', u')', u'\n', u'\n', u'\n', u'Accounts payable and accrued expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'249', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,014', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'113', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'159', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash provided by operating activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'103', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(2,178', u'\n', u')', u'\n', u'\n', u'\n', u'Cash flows from investing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Purchase of property, plant and equipment', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(137', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(211', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash used in investing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(137', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(211', u'\n', u')', u'\n', u'\n', u'\n', u'Cash flows from financing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Issuance of common stock', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,101', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Proceeds on line of credit', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'500', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Payments on line of credit', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(500', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash provided by (used in) financing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,101', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net increase (decrease)\xa0in cash and cash equivalents', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(34', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(288', u'\n', u')', u'\n', u'\n', u'\n', u'Cash and cash equivalents at beginning of period', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'694', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'982', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash and cash equivalents at end of period', u'\n', u'\xa0', u'\n', u'$', u'\n', u'660', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'694', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Supplemental disclosure', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash paid for interest', u'\n', u'\xa0', u'\n', u'$', u'\n', u'8', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash paid for taxes', u'\n', u'\xa0', u'\n', u'$', u'\n', u'7', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'The accompanying notes are an integral part of the financial statements.', u'\n', u'10\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nNotes to Financial Statements', u'\nYears Ended September\xa030, 2003 and 2002', u'\n', u'NOTE 1 \x97 ORGANIZATION AND OPERATION', u'\n', u'TherMatrx, Inc. (the Company) was incorporated in the state of Delaware on\nNovember\xa013, 1997. The Company is marketing a new medical device to treat\nBenign Prostatic Hyperplasia (BPH), which is a non-cancerous enlargement of the\nprostate gland. The Company is doing business throughout the United States.\n\n\n', u'NOTE 2 \x97 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES', u'\n', u'Method of Accounting\n\n\n', u'The Company prepares its financial statements using the accrual basis of\naccounting in accordance with generally accepted accounting principles accepted\nin the United States of America.\n\n\n', u'Cash and Cash Equivalents\n\n\n', u'Cash and cash equivalents include all monies in banks and highly liquid\ninvestments with maturity dates of less than 60\xa0days.\n\n\n', u'Inventory\n\n\n', u'Inventories are stated at the lower of cost or market.\n\n\n', u'Property and Equipment\n\n\n', u'Property and Equipment are carried at cost. Depreciation is provided using the\nstraight-line method at rates based on the following useful lives:\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Furniture and Fixtures\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'years', u'\n', u'\n', u'\n', u'Equipment\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3 \x96 5', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'years', u'\n', u'\n', u'\n', u'Leasehold Improvements\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1 \x96 3', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'years', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'Expenditures for major renewals and betterments that extend the useful lives of\nproperty and equipment are capitalized. Expenditures for maintenance and\nrepairs are charged to expense as incurred.\n\n\n', u'Use of Estimates\n\n\n', u'The process of preparing financial statements in conformity with generally\naccepted accounting principles requires management to make estimates and\nassumptions that affect the reported amounts of assets and liabilities and\ndisclosure of contingent assets and liabilities at the date of the financial\nstatements and reported amounts of revenues and expenses during the reported\nperiod. Actual results could differ from those estimates.\n\n\n', u'Advertising\n\n\n', u'The Company expenses advertising costs as they are incurred.\n\n\n\n', u'11\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nNotes to Financial Statements', u'\nYears Ended September\xa030, 2003 and 2002', u'\n', u'NOTE 2 \x97 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)', u'\n', u'Income Taxes\n\n\n', u'Income taxes are accounted for in accordance with the provisions of Statement\nof Financial Accounting Standards No.\xa0109. The provision for income tax\nexpense or benefit is based on income or loss reported for financial statement\npurpose adjusted for temporary and permanent differences between reported\nfinancial and taxable income or loss. The Federal Net Operating Loss, at\nSeptember\xa030, 2003 totals $7,367,458 and can be used to offset taxable income.\n\n\n', u'Revenue Recognition\n\n\n', u'Revenue is generally recognized when products are shipped. For equipment\nshipped to a customer for evaluation, revenue is recognized when the customer\nsigns a contract to purchase the equipment that has been delivered. (See Note\n12)\n\n\n', u'Patents\n\n\n', u'Patents are amortized on the straight-line basis over 15\xa0years.\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Costs', u'\n', u'\xa0', u'\n', u'$', u'\n', u'4,000,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Proceeds from Lawsuit', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(670,000', u'\n', u')', u'\n', u'\n', u'\n', u'Accumulated Amortization', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,313,500', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Patents, Net', u'\n', u'\xa0', u'\n', u'$', u'\n', u'2,016,500', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'NOTE 3 \x97 COMMITMENTS', u'\n', u'The Company has an operating lease for its office and warehouse space. The\nminimum monthly rental is $7,751. The lease expires on January\xa031, 2006. The\nCompany is responsible for its proportional share of real estate taxes,\noperating expenses, and escalation clauses.\n\n\n', u'The Company leases a vehicle under an operating lease which expires in April\n2006.\n\n\n', u'Future minimum rental payments:\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Year Ending', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'September 30', u'\n', u'\xa0', u'\n', u'Amount', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'2004', u'\n', u'\xa0', u'\n', u'$', u'\n', u'102,634', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2005', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'104,876', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2006', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'37,429', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total', u'\n', u'\xa0', u'\n', u'$', u'\n', u'244,939', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'12\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nNotes to Financial Statements', u'\nYears Ended September\xa030, 2003 and 2002', u'\n', u'NOTE 3 \x97 COMMITMENTS (CONTINUED)', u'\n', u'Rent expense for the years ended September\xa030, 2003 and 2002, was $99,550 and\n$99,069, respectively.\n\n\n', u'The Company has entered into several consulting agreements with doctors to\nprovide services on an hourly or fixed fee basis. Consulting fees, charged to\nexpense for the years ended September\xa030, 2003 and 2002, were $224,750 and\n$208,947, respectively.\n\n\n', u'NOTE 4 \x97 INVESTMENT', u'\n', u'Investment consists of a time deposit worth $10,424. The carrying value of\nthis investment approximates fair value because of the short-term maturity of\nthis financial instrument. This investment is collateral for an open line of\ncredit with a third party.\n\n\n', u'NOTE 5 \x97 CONCENTRATION OF CREDIT RISK', u'\n', u'The Company maintains cash accounts in two financial institutions. Balances in\nthese accounts exceed the federally insured limit of $100,000.\n\n\n', u'NOTE 6 \x97 RELATED PARTY', u'\n', u'The Company has entered into a consulting and non-compete, non-disclosure\nagreement with BSD Medical Corporation (BSD). BSD owns 78% of the Company\x92s\ncommon stock.\n\n\n', u'Consulting Agreement\n\n\n', u'The Company will use the expertise, on an \x93as needed\x94 basis, of employees of\nBSD in the development and monitoring the \x93FDA\x94 compliance regulations of a\nmedical device to treat Benign Prostatic Hyperplasia. For the years ended\nSeptember\xa030, 2003 and 2002, the Company has paid approximately $230,000 and\n$292,000 for these services, respectively.\n\n\n', u'Other\n\n\n', u'The Company purchased inventory and equipment from BSD totaling $1,161,007 and\n$1,856,031 for the years ended September\xa030, 2003 and 2002. Included in\nAccounts Payable is the amount due to BSD of $70,702.\n\n\n', u'Non-compete, Non-disclosure Agreement\n\n\n', u'BSD has entered into an agreement with the Company not to engage in any\nbusiness or provide any services in the treatment of any benign conditions or\ndiseases of the prostrate gland. BSD shall not disclose any \x93Confidential\nInformation\x94 of the clinical trials or the medical device used in such\ntreatments.\n\n\n\n', u'13\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nNotes to Financial Statements', u'\nYears Ended September\xa030, 2003 and 2002', u'\n', u'NOTE 7 \x97 LINE OF CREDIT', u'\n', u'The Company has two lines of credit with a commercial bank which provide\nborrowings up to $1,000,000 and $1,200,000.\n\n\n', u'The $1,000,000 line of credit bears interest at a variable rate, the Wall\nStreet Journal prime, and is payable monthly. The balance outstanding at\nSeptember\xa030, 2003 was $0.\n\n\n', u'The $1,200,000 line of credit bears interest at a variable rate, the Wall\nStreet Journal prime, and is payable monthly. The balance outstanding at\nSeptember\xa030, 2003 was $0.\n\n\n', u'Both of the lines of credit are secured by certain assets of the Company and a\npersonal guarantee of certain officers.\n\n\n', u'The agreement with the bank contains covenants which require the Company to\nachieve certain minimum performance levels. As of September\xa030, 2003 the\nCompany is in compliance with these covenants.\n\n\n', u'NOTE 8 \x97 CAPITALIZATION AND VALUATION OF INTANGIBLES', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Capitalization', u'\n', u'\xa0', u'\n', u'Date', u'\n', u'\xa0', u'\n', u'# of Shares', u'\n', u'\xa0', u'\n', u'Amount', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Common Stock', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11/13/97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,700,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'4,000,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'12/01/01', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'525,321', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'2,101,284', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Preferred Stock', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11/13/97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,300,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'3,250,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4/20/99', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,875,000', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'3,250,000', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'Common and Preferred Stock\n\n\n', u'The Board of Directors has unanimously approved, at the October\xa019, 2001\nmeeting, that the total number of shares of stock which the Corporation shall\nhave authority to issue will be increased to twenty million (20,000,000) shares\neach having a par value of $.001 per share, divided into (a)\xa0fourteen million\n(14,000,000) shares of common stock (the \x93Common Stock\x94) and (b)\xa0six million\n(6,000,000) shares of preferred stock (the \x93Preferred Stock).\n\n\n', u'Stock Options\n\n\n', u'The Company has a stock option plan that allows the Board of Directors to grant\nincentive stock options to employees and nonqualified stock options to\nemployees and consultants of the company. This plan was originally approved in\n1997, and was amended and restated in October of 2000. A total of 1,750,000\nshares of stock were reserved for issuance under this plan. As of September\n30, 2003 there were 109,209 shares available for future grants. Options expire\nten years after the date of grant and are subject to varying vesting schedules.\n\n\n\n', u'14\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nNotes to Financial Statements', u'\nYears Ended September\xa030, 2003 and 2002', u'\n', u'NOTE 8 \x97 CAPITALIZATION AND VALUATION OF INTANGIBLES (CONTINUED)', u'\n', u'Additionally the Board of Directors has approved special option grants. In\nOctober of 2001, the Board approved the grant of 118,687 options as part of a\nprivate offering to raise working capital. These options, priced at $4.00 per\nshare, vested immediately and expire at the end of May\xa02004.\n\n\n', u'In May of 2003, the Board approved a special option grant of 200,000 shares to\nan employee of the Company. These options, priced at $7.50 per share, vest\nover a 5-year period and expire in 10\xa0years.\n\n\n', u'The following table summarizes our option activity:\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Year ended September 30', u'\n', u'\xa0', u'\n', u'2003', u'\n', u'\xa0', u'\n', u'2002', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Number of', u'\n', u'\xa0', u'\n', u'Avg. Price', u'\n', u'\xa0', u'\n', u'Number of', u'\n', u'\xa0', u'\n', u'Avg. Price', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Options', u'\n', u'\xa0', u'\n', u'per Option', u'\n', u'\xa0', u'\n', u'Options', u'\n', u'\xa0', u'\n', u'per Option', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Options outstanding, beginning of year', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,756,601', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'2.49', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,446,347', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'2.17', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Options granted', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'206,387', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7.50', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'310,254', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4.00', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Options cancelled', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3,510', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4.00', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Options exercise', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Options outstanding, end of year', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,959,478', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3.01', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,756,601', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2.49', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'Valuation of Intangibles\n\n\n', u'In order to establish the value of the patents and patent rights contributed,\nthe Company compared the percentage of the shares acquired for cash with the\npercentage acquired for the rights to the patents. Based on the expectation\nthat the \x93Milestone Closing\x94 would be achieved, it was determined that the\nintangible assets contributed were worth $4,000,000 (Note 2). This asset is\nshown in the financial statements, as Patents, Net, and it will be amortized\nover 15\xa0years in accordance with generally accepted accounting principles. The\npatents and patent rights were contributed to the Company for common stock\nvalued at $4,000,000.\n\n\n', u'NOTE 9 \x97 RETIREMENT PLAN', u'\n', u'The Company maintains a SIMPLE retirement plan which allows for employee salary\ndeferral contributions as well as employer contributions. Employees must meet\ncertain compensation requirements to participate in the plan. Participants are\nvested 100% in both the employee salary deferral and the employer contribution.\nThe employer contributions for the years ended September\xa030, 2003 and 2002,\nwere $88,269 and $43,307, respectively.\n\n\n\n', u'15\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nNotes to Financial Statements', u'\nYears Ended September\xa030, 2003 and 2002', u'\n', u'NOTE 10 \x97 ECONOMIC DEPENDENCY', u'\n', u'The Company purchases from two vendors, of which one is a related party, the\ncontrol boxes of the TMX 2000 System.\n\n\n', u'The Company purchases all applicators from one supplier.\n\n\n', u'NOTE 11 \x96 OTHER INCOME', u'\n', u'Other income is primarily derived from licensing of certain company owned\npatents.\n\n\n', u'NOTE 12 \x96 REVENUE RESTATEMENT', u'\n', u'In July of 2004, the stock of Thermatrx, Inc. was sold to a third party. The\nrevenue recognition policy of the acquiring company is different than that of\nThermatrx, Inc. The financial statements for the years ended September\xa030, 2003\nand 2002 have been restated to reflect the revenue recognition policy of the\nacquiring company.\n\n\n', u'The acquiring company recognizes revenue when legal title to the good passes to\nits customers. The company reports sales net of estimated returns and\ndiscounts. Revenues from equipment sales are generally recognized when the\nequipment has been shipped and installed. Certain equipment sales occur under\na contract, which includes combined pricing on both the equipment and\nconsumable products. In these cases, a portion of revenue and related cost on\nthe equipment in the contract is recognized as consumable products are shipped\nover the life of the contract.\n\n\n', u'The adjustment for the year ended September\xa030, 2003 decreased income by\n$5,452, increased deferred cost by $13,444, and increased deferred revenue by\n$7,992.\n\n\n', u'The adjustment for the year ended September\xa030, 2002 decreased income by\n$88,915, increased deferred cost by $265,585, and increased deferred revenue by\n$354,500.\n\n\n\n\n', u'16\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.2\n', u'4\n', u'c88445exv99w2.htm\n', u'UNAUDITED BALANCE SHEETS\n', u'\n', u'exv99w2', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'EXHIBIT 99.2\n\n\n', u'TherMatrx, Inc.', u'\nBalance Sheet', u'\n(In thousands, except share and per share data)', u'\n', u'(Unaudited)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'June 30, 2004', u'\n', u'\xa0', u'\n', u'September 30, 2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash and cash equivalents', u'\n', u'\xa0', u'\n', u'$', u'\n', u'273', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'660', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Short term investments', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,761', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts receivable, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,189', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,238', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Inventories, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,532', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,486', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'174', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'154', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,929', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,548', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Property, plant and equipment, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'222', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'319', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Intangibles, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,850', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,017', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Investment in technology and other assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'18', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'44', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total assets', u'\n', u'\xa0', u'\n', u'$', u'\n', u'12,019', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'8,928', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Liabilities and Stockholders\x92 Equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts payable', u'\n', u'\xa0', u'\n', u'$', u'\n', u'247', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'325', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other accrued expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,220', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'912', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Deferred revenue and customer deposits', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'798', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'964', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,265', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,201', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Long-term liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'550', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Common stock, par value $.001 per share; authorized\n14,000,000 shares; issued and outstanding:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'3,225,321 shares', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,553', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,101', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Preferred stock, par value $.001 per share; authorized\n6,000,000 shares; issued and outstanding:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'5,175,000 shares', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,500', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,500', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Retained earnings', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3,299', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(6,424', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,754', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,177', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total liabilities and stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'$', u'\n', u'12,019', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'8,928', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'The accompanying notes are an integral part of the financial statements.', u'\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nStatements of Income and Retained Earnings', u'\n(In thousands)', u'\n', u'(Unaudited)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Three Months Ended', u'\n', u'\xa0', u'\n', u'Three Months Ended', u'\n', u'\xa0', u'\n', u'Nine Months Ended', u'\n', u'\xa0', u'\n', u'Nine Months Ended', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'June 30, 2004', u'\n', u'\xa0', u'\n', u'June 30, 2003', u'\n', u'\xa0', u'\n', u'June 30, 2004', u'\n', u'\xa0', u'\n', u'June 30, 2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Net sales', u'\n', u'\xa0', u'\n', u'$', u'\n', u'4,789', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'3,110', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'12,940', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'10,186', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cost of sales', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'880', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'808', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,035', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,860', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Gross profit', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,909', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,302', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,905', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,326', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Marketing and selling', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,657', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,372', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,814', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,266', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Research and development', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'148', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'322', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'377', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'815', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'General and administrative', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'735', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'516', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,078', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,779', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,540', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,210', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,269', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,860', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,369', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'92', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,636', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'466', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Interest income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Interest expense', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(5', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(2', u'\n', u')', u'\n', u'\n', u'\n', u'Other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'412', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'340', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(29', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'419', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(8', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'351', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(31', u'\n', u')', u'\n', u'\n', u'\n', u'Income before income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,788', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'84', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,987', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'435', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Provision for income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income', u'\n', u'\xa0', u'\n', u'$', u'\n', u'1,788', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'84', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'2,987', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'435', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Retained earnings, beginning of period', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($5,199', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($7,599', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($6,398', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($7,950', u'\n', u')', u'\n', u'\n', u'\n', u'Retained earnings, end of period', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(3,411', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(7,515', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(3,411', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(7,515', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'The accompanying notes are an intergral part of the financal statements.', u'\n', u'18\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nStatements of Cash Flow', u'\n(In thousands)', u'\n', u'(Unaudited)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Nine Month Period', u'\n', u'\xa0', u'\n', u'Nine Month Period', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Ended', u'\n', u'\xa0', u'\n', u'Ended', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'June 30, 2004', u'\n', u'\xa0', u'\n', u'June 30, 2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Cash flows from operating activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income', u'\n', u'\xa0', u'\n', u'$', u'\n', u'2,987', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'435', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Adjustments to reconcile net income to\nnet cash provided by operating activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Depreciation', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'277', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'254', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Changes in operating assets and liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts receivable', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(2,018', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(280', u'\n', u')', u'\n', u'\n', u'\n', u'Inventories', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,031', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,515', u'\n', u')', u'\n', u'\n', u'\n', u'Accounts payable and accrued expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'766', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'278', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(117', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(85', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash provided by operating activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,926', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(913', u'\n', u')', u'\n', u'\n', u'\n', u'Cash flows from investing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Purchase of property, plant and equipment', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(14', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(120', u'\n', u')', u'\n', u'\n', u'\n', u'Purchase of investments', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3,751', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(10', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash used in investing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3,765', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(130', u'\n', u')', u'\n', u'\n', u'\n', u'Cash flows from financing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Issuance of common stock', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'452', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Proceeds on line of credit', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'500', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash provided by (used in) financing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'452', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'500', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net increase (decrease)\xa0in cash and cash equivalents', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(387', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(543', u'\n', u')', u'\n', u'\n', u'\n', u'Cash and cash equivalents at beginning of period', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'660', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,203', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash and cash equivalents at end of period', u'\n', u'\xa0', u'\n', u'$', u'\n', u'273', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'660', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'The accompanying notes are an integral part of the financial statements.', u'\n', u'19\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'TherMatrx, Inc.', u'\nNotes to Financial Statements', u'\nPeriods Ended June\xa030, 2004 and June\xa030, 2003', u'\n(Unaudited)', u'\n', u'NOTE 1 \x97 ORGANIZATION AND OPERATION', u'\n', u'TherMatrx, Inc. was incorporated in the state of Delaware on November\xa013, 1997.\nTherMatrx is marketing a new medical device to treat Benign Prostatic\nHyperplasia (BPH), which is a non-cancerous enlargement of the prostate gland.\nTherMatrx is doing business throughout the United States.\n\n\n', u'The financial statements included in this Form 8-K have been prepared by\nTherMatrx, Inc., without audit. Certain information and footnote disclosures\nnormally included in financial statements prepared in accordance with generally\naccepted accounting principles have been condensed or omitted pursuant to these\nrules and regulations. The year-end balance sheet was derived from audited\nfinancial statements, but does not include all disclosures required by\ngenerally accepted accounting principles. These unaudited interim financial\nstatements should be read in conjunction with the TherMatrx\x92s financial\nstatements and related notes included elsewhere in this Form 8-K/A.\n\n\n', u'These statements reflect, in management\x92s opinion, all adjustments (which\ninclude only normal, recurring adjustments) necessary for a fair presentation\nof the financial position and the results of operations and cash flows for the\nperiods presented. The results of operations for any interim period may not be\nindicative of results for the full year.\n\n\n', u'NOTE 2 \x97 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES', u'\n', u'Revenue Recognition\n\n\n', u'Revenue is generally recognized when products are shipped. For equipment\nshipped to a customer for evaluation, revenue is recognized when the customer\nsigns a contract to purchase the equipment that has been delivered.\n\n\n', u'The company recognizes revenue when legal title to the good passes to its\ncustomers. The company reports sales net of estimated returns and discounts.\nRevenues from equipment sales are generally recognized when the equipment has\nbeen shipped and installed. Certain equipment sales occur under a contract,\nwhich includes combined pricing on both the equipment and consumable products.\nIn these cases, a portion of revenue and related cost on the equipment in the\ncontract is recognized as consumable products are shipped over the life of the\ncontract.\n\n\n', u'20\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.3\n', u'5\n', u'c88445exv99w3.htm\n', u'UNAUDITED PRO FORMA FINANCIAL INFORMATION\n', u'\n', u'exv99w3', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'EXHIBIT 99.3\n\n\n', u'UNAUDITED PRO FORMA FINANCIAL INFORMATION', u'\n', u'The following unaudited pro forma condensed combined financial statements are\npresented for illustrative purposes only and are not necessarily indicative of\nthe combined financial position or results of operations for future periods or\nthe financial position or results of operations that actually would have been\nrealized had American Medical Systems Holdings, Inc. and TherMatrx, Inc. been a\ncombined company during the specified periods. The unaudited pro forma\ncondensed combined financial statements, including the related notes, are\nqualified in their entirety by reference to, and should be read in conjunction\nwith, the historical financial statements and related notes of American Medical\nSystems Holdings, Inc., included in its Annual Report on Form 10-K and\nQuarterly Report on Form 10-Q filed with the Securities and Exchange Commission\non March\xa017, 2004, and August\xa012, 2004, respectively, and the historical\naudited financial statements and related notes of TherMatrx, Inc., included\nelsewhere in this Form 8-K/A.\n\n\n', u'The following unaudited pro forma condensed financial statements are accounted\nfor in accordance with Statement of Financial Accounting Standards No.\xa0141,\n\x93Business Combinations\x94. The pro forma adjustments are based upon preliminary\nestimates and available information. Final purchase accounting adjustments may\ndiffer from the pro forma adjustments presented. The pro forma condensed\ncombined financial statements are based on the respective historical financial\nstatements of American Medical Systems Holdings, Inc. and TherMatrx, Inc. and\nassumes the acquisition took place on January\xa04, 2004, and December\xa029, 2003,\nfor the statements of operations, and July\xa03, 2004, for the balance sheet. The\npro forma adjustments are based on the estimates and assumptions set forth in\nthe notes to such pro forma financial statements.\n\n\n', u'21\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'American Medical Systems Holdings, Inc.', u'\nPro Forma Condensed Balance Sheet', u'\n(Unaudited)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'AMS', u'\n', u'\xa0', u'\n', u'TherMatrx', u'\n', u'\xa0', u'\n', u'Pro Forma', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Pro Forma', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'July 3, 2004', u'\n', u'\xa0', u'\n', u'June 30, 2004', u'\n', u'\xa0', u'\n', u'Adjustments', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Combined', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash and cash equivalents', u'\n', u'\xa0', u'\n', u'$', u'\n', u'65,891', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'273', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(42,676', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1', u'\n', u')', u'\n', u'\xa0', u'\n', u'$', u'\n', u'23,488', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Short term investments', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,349', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,761', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'15,110', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts receivable, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'36,922', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,189', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'40,111', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Inventories, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,600', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,532', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'31', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(2', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'20,163', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Deferred income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,126', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'78', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(8', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,204', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,904', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'174', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(25', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(2', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,053', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'139,792', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,929', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(42,592', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'107,129', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Property, plant and equipment, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'23,471', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'222', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(29', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(2', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'23,664', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Goodwill, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'98,989', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'98,989', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Intangibles, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'15,215', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,850', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'29,150', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'46,215', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Deferred income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'12,783', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(7,242', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(8', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,541', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Investment in technology and other assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,260', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'18', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,278', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total assets', u'\n', u'\xa0', u'\n', u'$', u'\n', u'295,510', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'12,019', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(20,713', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'286,816', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Liabilities and Stockholders\x92 Equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts payable', u'\n', u'\xa0', u'\n', u'$', u'\n', u'3,648', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'247', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'3,895', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accrued compensation expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,290', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'918', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,208', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accrued warranty expense', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,319', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,319', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other accrued expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,459', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,100', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,559', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current portion of notes payable', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,363', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,363', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'28,079', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,265', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'30,344', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Long-term notes payable', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,523', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,523', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Contingent liability on acquisition', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,742', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(5', u'\n', u')(8)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,742', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Common stock', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'336', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,553', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(6,553', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(4', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'336', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Preferred stock', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,500', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(6,500', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(4', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Additional paid-in capital', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'208,201', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'208,201', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accumulated other comprehensive income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'584', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'584', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Retained earnings (accumulated deficit)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'52,787', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3,299', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(18,402', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(4', u'\n', u')(8)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'31,086', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'261,908', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,754', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(31,455', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'240,207', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total liabilities and stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'$', u'\n', u'295,510', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'12,019', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(20,713', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'286,816', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'See accompanying notes to unaudited pro forma combined financial statements.\n\n\n', u'22\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'American Medical Systems Holdings, Inc.', u'\nPro Forma Condensed Statement of Operations', u'\n(Unaudited)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'AMS', u'\n', u'\xa0', u'\n', u'TherMatrx', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Six Months Ended', u'\n', u'\xa0', u'\n', u'Pro Forma', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Pro Forma', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'July 3, 2004', u'\n', u'\xa0', u'\n', u'June 30, 2004', u'\n', u'\xa0', u'\n', u'Adjustments', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Combined', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Net sales', u'\n', u'\xa0', u'\n', u'$', u'\n', u'96,406', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'8,151', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'104,557', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cost of goods sold', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,977', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,155', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'20,132', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Marketing and selling', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'33,743', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,158', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'36,901', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Research and development', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,161', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'229', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,390', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'General and administrative', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,086', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,343', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,429', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Amortization of intangibles', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,119', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,550', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(6', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,669', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'71,086', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,885', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,550', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'79,521', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25,320', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,266', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,550', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25,036', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Royalty income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'921', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'921', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Interest income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'310', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(424', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(7', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(114', u'\n', u')', u'\n', u'\n', u'\n', u'Interest expense', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(449', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(445', u'\n', u')', u'\n', u'\n', u'\n', u'Other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(187', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(71', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(258', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'595', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(67', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(424', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'104', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Income before income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25,915', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,199', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,974', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25,140', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Provision for income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,459', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(720', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(8', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'8,739', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income', u'\n', u'\xa0', u'\n', u'$', u'\n', u'16,456', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'1,199', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(1,254', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'16,401', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income per share', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.49', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.49', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Diluted', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.47', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.47', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Weighted average common shares used in calculation', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'33,313', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'33,313', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Diluted', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'35,004', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'35,004', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'See accompanying notes to unaudited pro forma combined financial statements.\n\n\n\n\n', u'23\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'American Medical Systems Holdings, Inc.', u'\nPro Forma Condensed Statement of Operations', u'\n(Unaudited)', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'AMS', u'\n', u'\xa0', u'\n', u'TherMatrx', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Year Ended', u'\n', u'\xa0', u'\n', u'Pro Forma', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Pro Forma', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'January 3, 2004', u'\n', u'\xa0', u'\n', u'December 31, 2003', u'\n', u'\xa0', u'\n', u'Adjustments', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Combined', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Net sales', u'\n', u'\xa0', u'\n', u'$', u'\n', u'168,283', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'12,982', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'181,265', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cost of goods sold', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'27,353', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,432', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'30,785', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Marketing and selling', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'63,324', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,526', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'68,850', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Research and development', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'14,924', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'821', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'15,745', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'General and administrative', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'16,882', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,415', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'19,297', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Amortization of intangibles', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,160', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,100', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(6', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,260', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'126,643', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'12,194', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,100', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'141,937', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'41,640', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'788', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3,100', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'39,328', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Royalty income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,797', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,797', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Interest income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'476', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'867', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(881', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(7', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'462', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Interest expense', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,828', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,828', u'\n', u')', u'\n', u'\n', u'\n', u'Other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,004', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(44', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'960', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,449', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'823', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(881', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,391', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Income before income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'44,089', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,611', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3,981', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'41,719', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Provision for income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'15,039', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,453', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(8', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'13,586', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income', u'\n', u'\xa0', u'\n', u'$', u'\n', u'29,050', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'1,611', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'(2,528', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'28,133', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income per share', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.88', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.86', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Diluted', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.85', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.82', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Weighted average common shares used in calculation', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'32,854', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'32,854', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Diluted', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'34,313', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'34,313', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'See accompanying notes to unaudited pro forma combined financial statements.\n\n\n\n\n\n\n\n\n', u'24\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'American Medical Systems Holdings, Inc.', u'\nNotes to Unaudited Pro Forma Combined Financial Statements', u'\n', u'\n', u'\n', u'\n', u'1.', u'\n', u'\xa0', u'\n', u'Allocation of purchase price', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'For this presentation, the Company allocated the July\xa03, 2004, estimated\npurchase price of TherMatrx, Inc. as follows:', u'\n', u'\n', u'\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'(Amounts in thousands)', u'\n', u'\xa0', u'\n', u'Amount', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Tangible assets acquired, net of liabilities assumed', u'\n', u'\xa0', u'\n', u'$', u'\n', u'718', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'In-process research and development, net of tax effect', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'21,700', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Developed technology and other intangible assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'31,000', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Contingent liability on acquisition', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(10,742', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Initial purchase price and acquisition costs', u'\n', u'\xa0', u'\n', u'$', u'\n', u'42,676', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'The Company will make future cash payments to former Thermatrx, Inc.\nshareholders, based on the combined entity\x92s future sales of TherMatrx\nproducts. These payments are expected to be four times projected revenues\nduring the earn-out period ending December\xa02005. The present value of\nfuture payments is estimated to be $125 Million.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'The purchase price allocation to develop technology and other intangible\nassets and in-process research and development assumed was based on an\nindependent valuation study to determine the respective fair values.\nTangible assets acquired, net of liabilities assumed were stated at fair\nmarket value at the date of acquisition, based on management\x92s assessment.\nIn accordance with purchase accounting rules, the acquired in process\nresearch and development of $35.0 Million, will be expensed at an after tax\neffect amount of $21.7 Million.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'2.', u'\n', u'\xa0', u'\n', u'Key to Pro Forma Adjustments', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'The unaudited pro forma condensed combined balance sheet and statements of\noperations include the adjustments necessary to give effect to the purchase\nand to reflect the allocation of the purchase price to the fair value of the\nassets acquired as noted above, including the elimination of Thermatrx,\nInc.\x92s equity accounts. Summarized below are the pro forma adjustments\nnecessary to reflect the acquisition of Thermatrx, Inc. based upon the\npurchase method of accounting in accordance with SFAS 141, \x93Business\nCombinations\x94.', u'\n', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(1)', u'\n', u'\xa0', u'\n', u'To record cash used to consummate the acquisition, (including\nestimated closing costs of $2.2\xa0million).', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(2)', u'\n', u'\xa0', u'\n', u'To adjust tangible assets to fair value at date of\nacquisition.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(3)', u'\n', u'\xa0', u'\n', u'To record the value assigned to developed technology and\nother intangible assets.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(4)', u'\n', u'\xa0', u'\n', u'To eliminate the equity accounts of TherMatrx, Inc. and to\nreflect a $35\xa0million expense that would be recorded by the Company\nfor acquired in-process research and development.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(5)', u'\n', u'\xa0', u'\n', u'To record the excess of the estimated fair value of net\nassets acquired, over the initial purchase price.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(6)', u'\n', u'\xa0', u'\n', u'To record amortization expense relating to value assigned to\ndeveloped technology to be amortized over 10\xa0years.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(7)', u'\n', u'\xa0', u'\n', u'To reflect decreased interest income resulting from a\ndecrease in cash, for consideration paid.', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'(8)', u'\n', u'\xa0', u'\n', u'To record tax effect of pro forma income statement\nadjustments.', u'\n', u'\n', u'\n', u'25\n', u'\n', u'\n', u'\n', u'\n', u'EX-99.4\n', u'6\n', u'c88445exv99w4.htm\n', u'PRESS RELEASE\n', u'\n', u'exv99w4', u'\n', u' PAGEBREAK ', u'\n', u'\xa0', u'\n', u'\n', u'EXHIBIT 99.4\n\n\n', u'DATE: July\xa029, 2004\n\n\n', u'American Medical Systems Reports Record $49.1 Million', u'\nSales with 33 Percent Net Income Growth in Second Quarter', u'\n', u'Second Half Revenues, Aided by TherMatrx', u'\nAcquisition, Expected to Increase by Over 25%', u'\n', u'MINNEAPOLIS, July\xa029, 2004 \x96 American Medical Systems Holdings Inc. (NASDAQ:\nAMMD) reported another sales record of $49.1\xa0million in the second quarter of\n2004, a 16\xa0percent increase over sales of $42.2\xa0million in the comparable\nquarter of 2003 (14\xa0percent without gain from currency exchange rate changes).\nNet income in the quarter was $8.4\xa0million, or $0.24 per share, up 33\xa0percent\nfrom $6.3\xa0million, or $0.19 per share, in the comparable quarter of 2003.\n\n\n', u'Sales for the first six months of 2004 were $96.4\xa0million, up 18% from sales of\n$81.6\xa0million in 2003 (16\xa0percent without gain from currency exchange rate\nchanges). Net income in the six month period totaled $16.5\xa0million, or $0.47\nper share, up 40% from $11.8\xa0million, or $0.35 per share in 2003.\n\n\n', u'Douglas W. Kohrs, Chairman and Chief Executive Officer of American Medical\nSystems, commented, \x93Our worldwide ability to leverage across our broad product\nportfolio was again clear in the second quarter. Women\x92s continence products\nled our growth at 52% above 2003\x92s comparable period. Male continence\ncontinued its momentum with a 17% increase in the quarter. Erectile\nrestoration revenue was even with last year\x92s second quarter, but is poised to\nresume growth following the FDA\x92s clearance of our ', u'AMS 700 Tactile Pump', u'\x99\nannounced earlier this week. Our TherMatrx acquisition closed early in the\nthird quarter, thereby giving us another growth engine, and providing us the\nopportunity to work directly with our urology customers in meeting the needs of\nthe high-growth, in-office benign prostatic hyperplasia market.\x94\n\n\n\n', u'Outlook', u'\n', u'Inclusive of its recently closed acquisition of TherMatrx, AMS expects 2004\nrevenue to be in the range of $205 to $210\xa0million, generating EPS of $0.95 to\n$0.99. For the third quarter of 2004, the Company expects revenue to be in the\nrange of $49 to $51\xa0million. EPS for the third quarter is anticipated in the\nrange of $0.22 to $0.24.\n\n\n\n', u'Earnings Call Information', u'\n', u'American Medical Systems will host a conference call today at 5:00 p.m. (EST)\nto discuss its second quarter 2004 results. To access the call within the\nU.S., dial (800)\xa0309-5451, outside the U.S., (706)\xa0679-3605. A live web cast\nof the call will be available through the Company\x92s corporate website at\nwww.AmericanMedicalSystems.com and available for replay two hours after the\ncompletion of the call.\n\n\n\n', u'\xa0\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'About American Medical Systems', u'\n', u'American Medical Systems, headquartered in Minnetonka, Minnesota is a\ndiversified supplier of medical devices and procedures to cure erectile\ndysfunction, benign prostatic hyperplasia, incontinence, and other pelvic\ndisorders in men and women. Although not life threatening, these disorders can\nsignificantly diminish one\x92s quality of life and profoundly affect social\nrelation-ships. In recent years, the number of people seeking treatment has\nincreased markedly as a result of longer lives, higher quality-of-life\nexpectations and greater awareness of new treatment alternatives. American\nMedical Systems\x92 products reduce or eliminate the incapacitating effects of\nthese diseases, often through minimally invasive therapies. The Company\x92s\nproducts were used to treat over 100,000 patients in 54 countries during the\nlast year. More information about the Company and its products may be found at\nwww.AmericanMedicalSystems.com.\n\n\n\n', u'Forward Looking Statements', u'\n', u'Statements about the Company\x92s future product availability and sales are\nforward-looking statements subject to risks and uncertainties including the\ntiming and success of new product introductions, physician acceptance,\nendorsement, and use of the Company\x92s products, competitor activities, changes\nin reimbursement rates, and potential product recalls. These risks and others\nare more fully described in the Company\x92s Annual Report on Form 10-K for the\nyear ended January\xa03, 2004, and its other SEC filings. Actual results may\ndiffer materially from anticipated results.\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Contact:\n', u'\n', u'\xa0', u'\n', u'Carmen Diersen', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Executive Vice President and Chief Financial Officer', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'952-930-6495', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Carmen.Diersen@AmericanMedicalSystems.com', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Doug Kohrs', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Chairman and Chief Executive Officer', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'952-930-6118', u'\n', u'\n', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'Doug.Kohrs@AmericanMedicalSystems.com', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'2\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'American Medical Systems Holdings, Inc.', u'\nStatements of Operations', u'\n(In thousands, except per share data)\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Three Months Ended', u'\n', u'\xa0', u'\n', u'Six Months Ended', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'July 3, 2004', u'\n', u'\xa0', u'\n', u'June 28, 2003', u'\n', u'\xa0', u'\n', u'July 3, 2004', u'\n', u'\xa0', u'\n', u'June 28, 2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Net sales', u'\n', u'\xa0', u'\n', u'$', u'\n', u'49,093', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'42,224', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'96,406', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'81,571', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cost of sales', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,047', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,381', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,977', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'14,324', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Gross profit', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'40,046', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'34,843', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'78,429', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'67,247', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Marketing and selling', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,250', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'16,984', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'33,743', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'31,781', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Research and development', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,577', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,483', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,161', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,274', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'General and administrative', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,210', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,845', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,086', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,915', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Amortization of intangibles', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,058', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,039', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,119', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,104', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total operating expenses', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'27,095', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25,351', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'53,109', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'49,074', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Operating income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'12,951', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,492', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25,320', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'18,173', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Royalty income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'430', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'687', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'921', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,464', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Interest income', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'172', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'112', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'310', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'242', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Interest expense', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(248', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(698', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(449', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,424', u'\n', u')', u'\n', u'\n', u'\n', u'Other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(31', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'286', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(187', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'321', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total other income (expense)', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'323', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'387', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'595', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'603', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Income before income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'13,274', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,879', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25,915', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'18,776', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Provision for income taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'4,845', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,542', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,459', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'6,985', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income', u'\n', u'\xa0', u'\n', u'$', u'\n', u'8,429', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'6,337', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'16,456', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'11,791', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income per share', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.25', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.19', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.49', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.36', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Diluted', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.24', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.19', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.47', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'0.35', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Weighted average common shares\nused in calculation', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Basic', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'33,384', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'32,800', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'33,313', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'32,673', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Diluted', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'35,037', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'34,077', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'35,004', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'34,057', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'3\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'American Medical Systems Holdings, Inc.', u'\nCondensed Balance Sheets', u'\n(In thousands)\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'July 3, 2004', u'\n', u'\xa0', u'\n', u'January 3, 2004', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash and short-term investments', u'\n', u'\xa0', u'\n', u'$', u'\n', u'77,240', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'58,953', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts receivable, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'36,922', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'33,507', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Inventories', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,600', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'18,402', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Deferred taxes and other current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'8,030', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'8,533', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total current assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'139,792', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'119,395', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Property, plant and equipment, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'23,471', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25,489', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Goodwill and intangibles, net', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'114,204', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'116,455', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Deferred taxes and other assets', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'18,043', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,988', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total assets', u'\n', u'\xa0', u'\n', u'$', u'\n', u'295,510', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'279,327', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Liabilities and Stockholders\x92 Equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accounts payable', u'\n', u'\xa0', u'\n', u'$', u'\n', u'3,648', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'4,621', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Accrued liabilities and taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,068', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,996', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Current portion of notes payable', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,363', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'7,159', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total current liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'28,079', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'29,776', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Long-term notes payable', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'5,523', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'9,205', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'261,908', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'240,346', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total liabilities and stockholders\x92 equity', u'\n', u'\xa0', u'\n', u'$', u'\n', u'295,510', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'279,327', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'4\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'American Medical Systems Holdings, Inc.', u'\nCondensed Statements of Cash Flows', u'\n(In thousands)\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Six Months Ended', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'July 3, 2004', u'\n', u'\xa0', u'\n', u'June 28, 2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Cash flows from operating activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net income', u'\n', u'\xa0', u'\n', u'$', u'\n', u'16,456', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'11,791', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Adjustments to reconcile net income to net cash provided\nby operating activities:', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Depreciation', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3,466', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,865', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Loss on asset disposals', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(5', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Amortization of intangibles, including deferred financing costs', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,231', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,239', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Non-cash deferred compensation', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'88', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Income tax benefit related to stock option plans', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,294', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'892', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Change in net deferred taxes', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(618', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(992', u'\n', u')', u'\n', u'\n', u'\n', u'Changes in operating assets and liabilities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(4,128', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(5,155', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash provided by operating activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'18,699', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,728', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Cash flows from investing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Purchase of property, plant and equipment', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($1,443', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($1,599', u'\n', u')', u'\n', u'\n', u'\n', u'Purchase of businesses, net of cash acquired', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\x97', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(43,069', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash used in investing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(1,443', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(44,668', u'\n', u')', u'\n', u'\n', u'\n', u'Cash flows from financing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Issuance of common stock', u'\n', u'\xa0', u'\n', u'$', u'\n', u'4,590', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'1,269', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Payments on long-term debt', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3,478', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(3,319', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net cash provided by (used in) financing activities', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,112', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(2,050', u'\n', u')', u'\n', u'\n', u'\n', u'Effect of exchange rates', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(81', u'\n', u')', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'(40', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Net increase (decrease)\xa0in cash and cash equivalents', u'\n', u'\xa0', u'\n', u'$', u'\n', u'18,287', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'($35,030', u'\n', u')', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'5\n', u'\n', u' PAGEBREAK ', u'\n', u'\n', u'\xa0', u'\n', u'\n', u'American Medical Systems Holdings, Inc', u'\nSelected Sales Information', u'\n(In thousands)\n\n\n', u'\n', u'\n', u' Begin Table Head ', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'Three Months Ended', u'\n', u'\xa0', u'\n', u'Six Months Ended', u'\n', u'\n', u'\n', u'(in thousands)', u'\xa0', u'\n', u'\xa0', u'\n', u'July 3, 2004', u'\n', u'\xa0', u'\n', u'June 28, 2003', u'\n', u'\xa0', u'\n', u'July 3, 2004', u'\n', u'\xa0', u'\n', u'June 28, 2003', u'\n', u'\n', u' End Table Head ', u'\n', u' Begin Table Body ', u'\n', u'\n', u'Sales', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Product line', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Men\x92s health', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Erectile restoration', u'\n', u'\xa0', u'\n', u'$', u'\n', u'17,919', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'17,966', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'35,384', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'35,818', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Continence', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'12,266', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'10,471', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'24,432', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'20,503', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Prostate treatment', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,089', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'1,312', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,255', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2,511', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total men\x92s health', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'31,274', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'29,749', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'62,071', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'58,832', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Women\x92s health', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'17,819', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'12,475', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'34,335', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'22,739', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total', u'\n', u'\xa0', u'\n', u'$', u'\n', u'49,093', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'42,224', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'96,406', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'81,571', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Geography', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'United States', u'\n', u'\xa0', u'\n', u'$', u'\n', u'37,643', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'33,919', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'74,241', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'66,266', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Outside United States', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'11,450', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'8,305', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'22,165', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'15,305', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total', u'\n', u'\xa0', u'\n', u'$', u'\n', u'49,093', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'42,224', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'96,406', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'$', u'\n', u'81,571', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Percent of total sales', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Product line', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Men\x92s health', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Erectile restoration', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'37', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'43', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'37', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'44', u'\n', u'%', u'\n', u'\n', u'\n', u'Continence', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'25', u'\n', u'%', u'\n', u'\n', u'\n', u'Prostate treatment', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'2', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'3', u'\n', u'%', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total men\x92s health', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'64', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'70', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'64', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'72', u'\n', u'%', u'\n', u'\n', u'\n', u'Women\x92s health', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'36', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'30', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'36', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'28', u'\n', u'%', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'100', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'100', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'100', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'100', u'\n', u'%', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Geography\nUnited States', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'77', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'80', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'77', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'81', u'\n', u'%', u'\n', u'\n', u'\n', u'Outside United States', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'23', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'20', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'23', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'19', u'\n', u'%', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u'\n', u'Total', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'100', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'100', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'100', u'\n', u'%', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'100', u'\n', u'%', u'\n', u'\n', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\xa0', u'\n', u'\n', u' End Table Body ', u'\n', u'\n', u'\n', u'6\n', u'\n', u'\n', u'\n', u'\n', u'GRAPHIC\n', u'7\n', u'c88445c8844500.gif\n', u'GRAPHIC\n', u'\nbegin 644 c88445c8844500.gif\nM1TE&.#EA\\@%F`//CX^KJZO\'Q\\?CX^/_[\\*"@I("`@/\\```#_\nM`/__````__\\`_P#______RP`````\\@%F```(_@#_"1Q(4""]>0@3*IQ\'KZ!#\nM@0L1$HS(\\"%$BA(M:MS(L:/\'CR!#BAQ)LJ3)DRA3JES)LJ7+E0IBRIPY$P*^\nMA@\\IT(S)3J"DG0J&6/P)5(&DETB3*EW*M*G3IU"C2K58M&J;AT.`MA-X#RB%\nMA_.L3AU+MJS9LVC3JC59M:HZASIWWA/X+J:#F1,>5HVPMJ_?OX`#"QY,N+#A\nMPX@3*TXLDPMC.%$HQ+\\^B_KCLE#ZQ;5-[BSZ!#BQX-$W+1@A&T^@0*@:"\\\nMJ@=(RYY-NS;H"!&&Z-8-X=T[=A5R[];]P//`-A"WD0^Q^\\!Q0D0&C3I@(^\nM@NJ&M-$>H?)!!%0\\!*6V4WA$T?36:T6M-^"$%%:86!OK9*AA7@/-@Z&&ZUQ%\nMT#L?:M@&/`+!4V*&;', u'!U1/_S1X)0-5ABGFF"==2=,[#BE(\nM$X-FQD3FFW#&^1`[^-1IYYUXXM-C0;^Q(XDD!^"S3H_RX//.`;XEJNBADA`I\nMYZ.02@G/I)16:NFDO/`2WD`\'W./IIY(0*LFGI)9Z#Z"1IJKJC&WNE."6_JNU\nMR', u'`$H0TSJ@T4=323+A)!/.MN*ZL$#[RM3OU`0!G+#0SPY8L0+7?9:5`NM@\nM%K9(,OV;=K!2S]1CU3%=S;-#;55YL)M**Z"Q_J)$_]-IDES-N]F\\\\]Q3LD/P\nM^*81+X=RVKA*7Y]-$#L23\'`X1.S,2Z*,/JY3[#J6[5K!X0=4\\)5(T>:K0\'\\C\nMI?US3\'T+5%W0\\PQ10>S_M),:`ST39#J\']P2\'^TC>#;_=Y025/L$$%$C.5ML*\nM,`RW`G++U/L_&Q?UL(UWZ]VPFP*-\'9/S30MT0$P20E@R9E3%W;[WWT.-4N0%\nM9;\\VI^#_,T%0!1Z_JI3`)K`M1+Z#:1[$DA-07PX$\'4', u"0`;Y/`1+`&`$_TDC^_:.+'=E)&PORQ9:%40$", u'DLDL]5(5"=)()GVLI4#B4@$(\'*7J!H@\\1', u'#$\\OV74HNW`B3P^^J=V3\'0^)`5I.2G4O5AY#UG(N\\N+@NG(*OZ3(.S+RC(\'\nM$J\\AJ&E_0E0GV";X08O`', u'E`Q,>2AC[DH7&\\J^,7YO5C8+"5`Y)#YQ\nMIM)-]INL0![3DQ7"$I\'+Y$SH!E+5>$)6BB"Y_IMBW3C4M*JC#:A]QV8F^4^G3B9#TIC[ZY\nMSZ8AJ2IN:-+1]PFDJEUD+C8)>IR8D*RJ#H\'0B7C"S,=ZY&[X\\%1?(RG7OL5K\nM>[I%RROE\\EL7TE6:U:VI\'&E9D->]PW`>S&!,T.3$TBI@H=F:YT?HZ#RM.5*?\nM1BNA0$+HR`F;[WX>06=1++N1\\OU#GM=$FC#GM1AG8+H!(@;P9`$;NL0=E`G.SMN@UB)7"TG]I*AABGO\nM;(;,Z5(_S]0OV4]N$1.!Y.Q&.+J)P`-\\>N\'5>9`!$>Y.3\'(#`?R,]RZI@0"O\nMY-QK!4`@-]K2C0.4X\\%E+WL(#A".M)7C4UA3V]H^S3:U7TWM!SR;-T%9W2\\?\nM(T]C\\YTWO>MO[WOC.M[[WS>]^BX=FTO6WP->]\nMKR`/_."E]K")$', u'K6T,/87/I`=UY@.\'0Q.?IG\')6R(\'`M%I-`>E"X`$BDD"4Y\'&5\nM%PXA26TPCB1*)H]P0GI9(V(@1`#F3GS$A`\'-.0##)I">-', u'5MS2J9#E#PL=6%)#/V+P&\'A#H"2_8P8!9U:EA[&B.Y1IV#WDT\nMYT.-]S#?2/RC6L.;QH#03NL;\'&E@QT_PCCK.@A6O_PE)O.F:7:U9$>"FB1\nM/K$16;80)$B->8\\^\'5)[PTKX&H%@>;@C7GNMV$&!P:>D+G0C2#Q:1H]I\\4(R\nMQ7HQX"8P%P(>C)TTGL>Z](9U\'_$%`IZ)`(J0_OR/Y#LUE1$(FS@K$&383_"X\nMG\'P`ZQ_`I', u"TFNI.^'GO^;IG]^@", u')]\'?$!>Q9DVG!$O`3:(*#/]A\\\'4$!1]%W+Q)\\>T9#=G8`*:-^\nM(EA\'WL."2I47ZS!(W@,S9,=.9P9@-JA;&,*%`B$/#M`&H>.#W=,[G/?\'B$(1X\'"(R`=`,W/8BKO2?`IP%_D";&`Q\nM2HX!/MW2$&/C(>$1+\\Q"A]UW%;SB02)2%^$T$!&&8`EV6I*8A+5G34JB-\\Z\'\nM,\\671[+WC6]B/T?#$@5`%B60&/H1-5*69GEL2:8N9GP9F', u'"!NHJBAFW(P(:BD[#%@_F&5$F\'!"_W1BO!#)XU7,H0(?.Q0?]XHE+X8`', u'_@3N\'Y$!)03B32/TACALJ8?$EV?_!3I]BS+MYX7\'F!\nMI9-*#_!@I&J:@8)Z*SLQHR&A>M2C-PX0)5D$$=/R$X+B(S,1&_OW?KPP:;4J\nM$(W8,/@02B^EIMYS/OC`,!206Y&J\'J.$9/$P+5U1JL=Q\';=\'=ILW=C)H5?:\'\nM#R74!FH*@K_:\'A[\'E"/!#ENQ\'Q0V%^W(3NEQBY3%)7WF-[I2>^PTIFZ$(EDQ\nM6BCBHGBJ2\'@T`:NVHU\'2A*NAK)_WC+(#LOG2$/%`JR+(L&0DLG*:,O;J_H9D\nMY#SY.AY&21,NZ1%4*(+M$$H..`3SPK`$Y)M-%#3Q0H\\Q\nM>QX9QZ\\B(2.`,RLTUAQCY!DXXAI[@E$2DBD\'H"Q9@A,5D7@\'[NXF[NZN[N\\V[N^^[O`&[S".[S$\n=6[S&>[S(F[S*N[S,V[S.^[S0&[W2.[WV$A```#L_\n`\nend\n\n', u'\n', u'\n', u'\n', u'GRAPHIC\n', u'8\n', u'c88445c8844501.gif\n', u'GRAPHIC\n', u'\nbegin 644 c88445c8844501.gif\nM1TE&.#EA``$B`/X2$A(R,C)24E)R', u'WN?GY^_O[_?W]_______________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM____________________________________________________________\nM_____________________RP```````$B```(_@`_"!Q(L*#!@P@3*ES(L*\'#\nMAQ`C2IQ(L:+%BQ@S:MS(L:/\'CR!#0O2008("!QY$JES)LJ7+CB0=$```0("&\nMESASZMQYL$,\'#ATT>I!`($"""0L`0.#)M*G3CAN0#@#@(&.\'"`$(4/#@P8\'2\nMIV`Q', u'S*#A`.!#A0`,`#C!X@!!@P06!7`!3,-M5008&""!A20IPPH(%>\nMD!XN)`A@H(\'B`1DNQJWY0\'`\'M1P.(_PIV..&!G,+)$`0H*I=#IT16@#``&P\'\nM#100*+B06C(%`0(8D%V2VF.$``/D$07M\'_+-"\nMA`8`!OC``Q%0H(%R`G5`@5KG!6`81Q2L-=\\\'&@2`P$!8+850!HLI,"%/\'E0P\nM@``+7,!`>A5@])E10%%`P``/!&61!TD=,*$\'%A2&H$83&(`>34`&&4!;$,A8\nMD`A(0M$%X5(:D`$U_5:`G!`[TZ8`$)S*@\')D`1"#8`@64M1$"`(AI\nM5P$#.\'H7`E!^J5:(`NKK$U78`#/G`@0E%JZ&E:_TJ&09M-28!;01U\nM:!!L%M16`6N6::"```Z:C%"P;7;`:$T!*$DM16A&\nML%VS9A?T6@83"Y6!5P`TH+5', u'%UC0P%3X551P`(YJ0-IO!7%G0`$(\nM&/Y15^;%G-="#_CVJ00"H/Y0!DM_L($!C`,Y0`(///L!!U(2,%--NF7DP:^3\nMV7A0D@H\\ZY^4', u'SIV/`8@\nM8&P?X$RE2.(^`B!@`=3"`-9FI[8#1(H@\'%@>8Q#@`))Y#R$;4$N1%(*!!09%\nM`WUJVT$8=@\'0N"', u'6`#$G```QI@M@LT2X1/[57N(!Y(@+/$\nMJ!`+H"=M%!J/!]KB.C1Y[I@,0"AC\'*`EFOA(B":Y#P4H@6@XA0/&.2_M)4"M"`KRT0`@?B@/L$H*?%\nM!"EF64D/M134*W$UP`%>!%>0#C"!LA0SK1*)D`1E`P&S;N"Z[RP)IF@2@.92\nM8#H$2``%,K`\\`43FE!*0;\\SI?!%:=,A`!KR`@L@]P0`*0.!"N*.4]GUJ8/^!DG-=YC6I$OT$>MHS7:(2\\S*\\3J,`%\nM^-R9Y^VX`[\\^"`=0#9%', u'"!V[\nM%!4J#25S-:8``]BJF78[)0("H$NXW9T0[$"&WOAN2@C\n', u'\n', u'\n-----END PRIVACY-ENHANCED MESSAGE-----\n']